Santarus Inc

Santarus — Technical Presentation (May 2011)

25 slides from Santarus's technical presentation, May 9, 2011

  1. Slide 1: Budesonide MMX 9 mg for induction of remission of active mild-to-moderate ulcerative colitis

    Budesonide MMX(r) 9 mg for the induction of remission of active mild-to-moderate ulcerative colitis Data from a multicenter, randomized, double-blind, placebo- controlled study in Europe, Russia, Israel, and Australia 7 May 2011 Simon Travis1, William J Sandborn2, Silvio Danese3, Limas Kupcinskas4,

  2. Slide 2: Conflicts Of Interest

    Conflicts Of Interest I do have a relevant financial or other relationship with a commercial organization that could influence the content of my presentation Organisation/Company: Abbott; Elan; Cosmo Pharmaceuticals; Ferring; Merck/MSD; Santarus; Shire; Tillotts; UCB Pharma; Vifor; Warner Chilcott I

  3. Slide 3: Budesonide MMX

    Budesonide MMX(r) Budesonide Highly potent non-halogenated corticosteroid Low systemic bioavailability Established value as topical therapy in UC and targeted delivery for CD Budesonide MMX(r) Gastro-resistant MMX(r) delivery 3

  4. Slide 4: Budesonide and the Multi Matrix System (MMX)

    Budesonide and the Multi Matrix System (MMX(r)) Inert matrix Hydrophilic matrix Gastroprotectant layer LV hydrophilic - amphipatic polymer matrix HV hydrophilic polym. matrix Inert matrix material Drug (+ excipient) 4

  5. Slide 5: Objectives

    Objectives To evaluate the efficacy and safety of budesonide MMX(r) 6 and 9 mg/day in patients with mildly to moderately active ulcerative colitis 5

  6. Slide 6: Study Design

    Study Design 8 week randomized, double-blind, placebo-controlled, multicenter, parallel group trial 80 sites in Europe, Russia, Israel, and Australia Patients with mildly to moderately active ulcerative colitis Randomized in a 1:1:1:1 ratio to: Budesonide MMX(r) 6 mg/day Budesonide MMX(r) 9 mg/day E

  7. Slide 7: Key Inclusion/Exclusion Criteria

    Key Inclusion/Exclusion Criteria Male or female, 18-75 years History of UC for ^ 6 months Excluded patients with limited distal proctitis (from anal verge up to 15 cm above the pectineal line) Experiencing a mild or moderate flare of UC with an UC Disease Activity Index (UCDAI, Sutherland Index) sco

  8. Slide 8: Evaluation of Efficacy: Primary Endpoint

    Evaluation of Efficacy Individual Assessments (scored 0-3: UC Disease Activity Index (UCDAI, Sutherland Index) Stool Frequency Rectal Bleeding Colonoscopy Physician's Rating of Disease Activity Primary Endpoint Remission at Week 8 defined as UCDAI score ^ 1 with: Rectal bleeding and stool frequency

  9. Slide 9: Evaluation of Efficacy: Secondary Endpoints

    Evaluation of Efficacy Secondary endpoints Clinical Improvement defined as a ^ 3 point reduction in UCDAI from Baseline to Week 8 Endoscopic Improvement defined as a ^ 1 point reduction in the mucosal appearance score of the UCDAI from Baseline to Week 8 Other endpoint Symptom Resolution defined as

  10. Slide 10: Statistical Analysis

    Statistical Analysis Primary efficacy analysis Superiority of budesonide MMX(r) 6 mg or 9 mg versus placebo ^ = 0.025 (2-sided) Study not powered for comparisons of budesonide MMX(r) 6 mg versus budesonide MMX(r) 9 mg or budesonide MMX(r) 6 mg or 9 mg versus vs. Entocort(r) EC Analysis performed on

  11. Slide 11: Patient Disposition

    Patient Disposition 11 101 patients excluded from modified ITT analysis 50 for GCP violations 48 for normal histology at baseline 1 for major entry criteria violation 2 not randomized through IVRS Placebo 89 patients Budesonide MMX(r) 9 mg 109 patients Budesonide MMX(r) 6 mg 109 patients Entocort(r)

  12. Slide 12: Baseline Characteristics

    Baseline Characteristics Baseline Characteristics 12

  13. Slide 13: Phase III Study Results: Primary Efficacy Endpoint

    Budesonide MMX(r) Phase 3 Study Results Primary Efficacy Endpoint (CHART) % Remission * N=89 N=109 N=109 N=103 Remission, n(%) 4 (4.5) 19 (17.4) 9 (8.3) 13 (12.6) ^ vs. Placebo -- 12.9% 3.8% 8.1% P-value -- 0.0047* 0.2876 0.0481+ * Statistically significant (p < 0.025) + Statistically significant (p

  14. Slide 14: Primary Endpoint Sensitivity Analysis

    Primary Endpoint Sensitivity Analysis: Previously Excluded Patients set to "Non-responders" (CHART) % Remission * N=129 N=126 N=128 N=126 Remission, n(%) 4 (3.1) 19 (15.1) 9 (7.0) 13 (10.3) ^ vs. Placebo -- 12.0% 3.9% 7.2% P-value -- 0.0008* 0.1505 0.0209+ * Statistically significant (p < 0.025) + S

  15. Slide 15: Study Results: Secondary Endpoints

    Budesonide MMX(r) Phase 3 Study Results Secondary Endpoints 15 PlaceboN= 89n (%) MMX(r) 9 mgN= 109n (%) MMX(r) 6 mgN= 109n (%) Entocort(r) ECN= 103n (%) Clinical Improvement Status* (Yes) 30 (33.7) 46 (42.2) 28 (25.7) 34 (33.0) Difference between Active & Placebo 8.5% -8.0% -0.7% P-value 0.2215 0.21

  16. Slide 16: Other Endpoint: Symptom Resolution

    Budesonide MMX(r) Phase 3 Study Results Other Endpoint: Symptom Resolution (Rectal bleeding AND stool frequency = 0 at Week 8) (CHART) % Symptom Resolution * N=89 N=109 N=109 N=103 Symptom Resolution (yes) n(%) 10 (11.2) 26 (23.9) 15 (13.8) 19 (18.4) ^ vs. Placebo -- 12.6% 2.5% 7.2% P-value -- 0.022

  17. Slide 17: Summary of Treatment-Emergent Adverse Events

    Budesonide MMX(r) Phase 3 Study Results Summary of Treatment-Emergent Adverse Events (TEAEs) 17 PlaceboN=129n (%) MMX(r) 9 mgN=128n (%) MMX(r) 6 mgN=128n (%) Entocort(r) ECN=126n (%) TotalN=511n (%) Treatment Emergent AEs 57 (44.2) 71 (55.5) 80 (62.5) 69 (54.8) 277 (54.2) Related 1 31 (24.0) 33 (25.

  18. Slide 18: Most frequently reported TEAEs

    Budesonide MMX(r) Phase 3 study results Most frequently reported TEAEs (^5% in any treatment group) 18 Preferred Term PlaceboN=129n (%) MMX(r) 9 mgN=128n (%) MMX(r) 6 mgN=128n (%) Entocort(r) ECN=126n (%) TotalN=511n (%) Patients with any TEAE 57 (44.2) 71 (55.5) 80 (62.5) 69 (54.8) 277 (54.2) Colit

  19. Slide 19: Effect of Budesonide MMX on Morning Plasma Cortisol

    Effect of Budesonide MMX(r) on Morning Plasma Cortisol 19 19 Symbols indicate mean plasma cortisol level for each visit for each treatment. Error bars indicate 25th and 75th percentiles. Treatments are offset for readability. Numbers at the bottom of the graph are the number of patients at each visi

  20. Slide 20: Signs and Symptoms of Glucocorticoid Effects

    Signs and Symptoms of Glucocorticoid Effects* 20 Effect PlaceboN=129N (%) MMX(r) 9 mgN=128N (%) MMX 6 mgN=128N (%) EntocortN=126N (%) Overall 11 (8.5) 7 (5.5) 7 (5.5) 12 (9.5) Moon Face 4 (3.1) 2 (1.6) 0 (0.0) 1 (0.8) Striae Rubrae 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) Flushing 1 (0.8) 0 (0.0) 1 (0.8) 1 (

  21. Slide 21: Conclusions

    Conclusions Budesonide MMX(r) 9 mg administered once daily was safe and effective for inducing remission in patients with mildly-to- moderately active UC Remission with budesonide MMX(r) 9 mg was superior to placebo (17.4% versus 4.5%; p-value = 0.0047) No significant differences between the study g

  22. Slide 22: Study investigators

    P. Gibson R. Leong A. Keegan T. Borody G. D'Haens A Maelt B. Margus J. Lind R. Salupere M. Lemann J.L. Dupas Y. Bouhnik Y. Niv Y. Avni A Fich M. Vecchi F. Luzza S. Danese V. Savarino G.C. Sturniolo M. Zoli C. Prantera S. Peralta R. Cannizzaro |. Tolmanis G.Acute E. Kazenaite L. Kupcinskas R. Vanagai

  23. Slide 23: Back-up Slides

    Back-up Slides

  24. Slide 24: Rationale For Exclusion Of Patients With Normal Histology

    Rationale For Exclusion Of Patients With Normal Histology Need independent confirmation that symptoms at trial entry were due to active UC, to ensure homogeneity of the patient cohort and integrity of the study European Medicines Agency (EMA) guidelines for clinical trials in active UC advise exclus

  25. Slide 25: Contrasting Remission Rates: Lialda and Budesonide MMX

    Contrasting Remission Rates Lialda(r) and Budesonide MMX(r) Protocol Design Differences Lialda(r) and Budesonide MMX(r) Protocol Design Differences Lialda(r) and Budesonide MMX(r) Protocol Design Differences 24

Santarus — Technical Presentation (May 2011) on 6ix